IL-23 Antibodies in Psoriasis - a Non-Clinical Perspective

被引：2
|
作者：
Zhou, L. [1 ]
Wang, Y. [2 ]
Wan, Q. [1 ]
Perron, D. [1 ]
Zhu, R. [1 ]
Wang, L. [1 ]
Gauld, S. [2 ]
Veldman, T. [1 ]
机构：
[1] Abbvie Biores Ctr, Worcester, MA USA
[2] Abbvie, N Chicago, IL USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 09期
关键词：
D O I：
10.1016/j.jid.2019.07.396
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
394
引用
收藏
页码：S282 / S282
页数：1
相关论文
共 50 条
  • [1] A non-clinical comparative study of IL-23 antibodies in psoriasis
    Zhou, Li
    Wang, Yibing
    Wan, Qi
    Wu, Fei
    Barbon, Jeffrey
    Dunstan, Robert
    Gauld, Stephen
    Konrad, Mark
    Leys, Laura
    McCarthy, Richard
    Namovic, Marian
    Nelson, Christine
    Overmeyer, Gary
    Perron, Denise
    Su, Zhi
    Wang, Leyu
    Westmoreland, Susan
    Zhang, Jun
    Zhu, Rui
    Veldman, Geertruida
    [J]. MABS, 2021, 13 (01)
  • [2] IL-23 Inhibitors for Psoriasis
    Beck K.M.
    Yang E.J.
    Sekhon S.
    Bhutani T.
    [J]. Current Dermatology Reports, 2018, 7 (2) : 119 - 124
  • [3] Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review
    Norden, A.
    Moon, J. Y.
    Javadi, S. S.
    Munawar, L.
    Maul, J-T
    Wu, J. J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1171 - 1177
  • [4] Targeting IL-23 in psoriasis: current perspectives
    Fotiadou, Christina
    Lazaridou, Elizabeth
    Sotiriou, Eleni
    Ioannides, Demetrios
    [J]. PSORIASIS-TARGETS AND THERAPY, 2018, 8 : 1 - 5
  • [5] Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies
    Ting-Ting Zhang
    Junli Ma
    Kenneth R. Durbin
    Timothy Montavon
    Susan E. Lacy
    Gary J. Jenkins
    Stella Doktor
    J. Cory Kalvass
    [J]. The AAPS Journal, 21
  • [6] Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies
    Zhang, Ting-Ting
    Ma, Junli
    Durbin, Kenneth R.
    Montavon, Timothy
    Lacy, Susan E.
    Jenkins, Gary J.
    Doktor, Stella
    Kalvass, J. Cory
    [J]. AAPS JOURNAL, 2019, 21 (05):
  • [7] The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
    Girolomoni, G.
    Strohal, R.
    Puig, L.
    Bachelez, H.
    Barker, J.
    Boehncke, W. H.
    Prinz, J. C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1616 - 1626
  • [8] Differentiation of therapeutic antibodies targeting IL-23
    Krueger, J. G.
    Eyerich, K.
    Greving, C.
    Sachen, K.
    Hammaker, D.
    Bao, P.
    Lacy, E.
    Elloso, M.
    Orlovsky, Y.
    McInnes, I.
    Fourie, A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B26 - B26
  • [9] IL-23 inhibitors for moderate-to-severe psoriasis
    Ibler, Erin
    Gordon, Kenneth B.
    [J]. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (03) : 158 - 162
  • [10] Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors
    Edward Hadeler
    Megan Mosca
    Julie Hong
    Nicholas Brownstone
    Tina Bhutani
    Wilson Liao
    [J]. Current Dermatology Reports, 2021, 10 : 6 - 15
12345